Keros Therapeutics, Inc.KROSNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-55.13%
↓ 750% below average
Average (26q)
8.48%
Historical baseline
Range
High:104.93%
Low:-55.13%
Volatility
1886.9%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -55.13% |
| Q2 2025 | -10.69% |
| Q1 2025 | 6.75% |
| Q4 2024 | -7.30% |
| Q3 2024 | 21.50% |
| Q2 2024 | 5.90% |
| Q1 2024 | 2.04% |
| Q4 2023 | 9.82% |
| Q3 2023 | 4.94% |
| Q2 2023 | 4.64% |
| Q1 2023 | 25.03% |
| Q4 2022 | 18.19% |
| Q3 2022 | -9.63% |
| Q2 2022 | 28.78% |
| Q1 2022 | -4.01% |
| Q4 2021 | 26.98% |
| Q3 2021 | 48.57% |
| Q2 2021 | -13.15% |
| Q1 2021 | 18.82% |
| Q4 2020 | 15.24% |
| Q3 2020 | 15.57% |
| Q2 2020 | -14.81% |
| Q1 2020 | 104.93% |
| Q4 2019 | 7.97% |
| Q3 2019 | -14.30% |
| Q2 2019 | -7.60% |
| Q1 2019 | 0.00% |